cas 3235-69-6|| where to buy morpholin-4-ylacetic acid

Product Name:morpholin-4-ylacetic acid

IUPAC Name:2-(morpholin-4-yl)acetic acid

Packing Unit	Available Stock	Price($)
CM112622-25g	in stock	ŔƄ
CM112622-100g	in stock	źǯǯ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3235-69-6 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:3235-69-6; Molecular Formula:C6H11NO3; Melting Point:-; Smiles Code:O=C(O)CN1CCOCC1; Density:

: Catalog Number:CM112622; Molecular Weight:145.16; Boiling Point:; MDL No:MFCD00504633; Storage:

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Zetomipzomib; Kezar Life Sciences announces clinical hold of Zetomipzomib IND for treatment of lupus nephritis(LN). Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders.
LN is a disease comprising a spectrum of vascular, glomerular and tubulointerstitial lesions and develops in approximately 50% of SLE patients within 10 years of their initial diagnosis. LN is associated with considerable morbidity, including an increased risk of end-stage renal disease requiring dialysis or renal transplantation and an increased risk of death. There are limited approved therapies for the treatment of LN. Management typically consists of induction therapy to achieve remission and long-term maintenance therapy to prevent relapse.